Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer

BACKGROUND: The United States Food and Drug Administration recently approved a Ki-67 immunohistochemistry (IHC) assay to identify patients with early breast cancer at high disease recurrence risk. The Oncotype Dx Breast Recurrence Score® assay has been validated in hormone receptor-positive (HR+), h...

Descripción completa

Detalles Bibliográficos
Autores principales: Crager, Michael, Wijayawardana, Sameera R., Gruver, Aaron M., Blacklock, Andrea, Russell, Christy, Baehner, Frederick L., Sapunar, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623921/
https://www.ncbi.nlm.nih.gov/pubmed/36320066
http://dx.doi.org/10.1186/s13058-022-01571-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623921/
https://www.ncbi.nlm.nih.gov/pubmed/36320066
http://dx.doi.org/10.1186/s13058-022-01571-7

Ejemplares similares